News
Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback